Next Article in Journal
Is the Benefit–Risk Ratio for Patients with Transfusion-Dependent Thalassemia Treated by Unrelated Cord Blood Transplantation Favorable?
Next Article in Special Issue
Models in the Research Process of Psoriasis
Previous Article in Journal
A Novel Mutation in the Fibrinogen Bβ Chain (c.490G>A; End of Exon 3) Causes a Splicing Abnormality and Ultimately Leads to Congenital Hypofibrinogenemia
Previous Article in Special Issue
Treatment Approaches to Moderate to Severe Psoriasis
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(11), 2471; doi:10.3390/ijms18112471

Advanced Glycation End Products in the Pathogenesis of Psoriasis

Section of Dermatology, Department of Medicine, University of Verona, 37126 Verona, Italy
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 22 October 2017 / Revised: 7 November 2017 / Accepted: 15 November 2017 / Published: 20 November 2017
(This article belongs to the Special Issue Psoriasis)
View Full-Text   |   Download PDF [812 KB, uploaded 20 November 2017]   |  

Abstract

Advanced glycation end products (AGEs) are extremely oxidant and biologically reactive compounds, which form through oxidation of sugars, lipids and amino acids to create aldehydes that bind covalently to proteins. AGEs formation and accumulation in human tissues is a physiological process during ageing but it is enhanced in case of persistent hyperglycemia, hyperlipidemia and oxidative or carbonyl stress, which are common in patients with moderate to severe psoriasis. Exogenous AGEs may derive from foods, UV irradiation and cigarette smoking. AGEs elicit biological functions by activating membrane receptors expressed on epithelial and inflammatory cell surface. AGEs amplify inflammatory response by favoring the release of cytokines and chemokines, the production of reactive oxygen species and the activation of metalloproteases. AGEs levels are increased in the skin and blood of patients with severe psoriasis independently of associated metabolic disorders. Intensified glycation of proteins in psoriasis skin might have a role in fueling cutaneous inflammation. In addition, AGEs released from psoriatic skin may increase metabolic and cardiovascular risk in patients with severe disease. View Full-Text
Keywords: advanced glycation end products; psoriasis; inflammation advanced glycation end products; psoriasis; inflammation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Papagrigoraki, A.; Maurelli, M.; del Giglio, M.; Gisondi, P.; Girolomoni, G. Advanced Glycation End Products in the Pathogenesis of Psoriasis. Int. J. Mol. Sci. 2017, 18, 2471.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top